Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Wednesday.
VRTX has been the subject of a number of other reports. Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Truist Financial upped their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Wells Fargo & Company downgraded Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 target price for the company. in a research report on Thursday, January 30th. Oppenheimer downgraded Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Thursday, December 19th. Finally, Stifel Nicolaus upped their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a "hold" rating in a research report on Monday, December 16th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $505.61.
Check Out Our Latest Report on Vertex Pharmaceuticals
Vertex Pharmaceuticals Stock Performance
NASDAQ:VRTX traded up $3.91 during mid-day trading on Wednesday, hitting $484.24. 1,443,962 shares of the stock were exchanged, compared to its average volume of 1,540,196. The stock has a market capitalization of $124.35 billion, a price-to-earnings ratio of -220.11, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The firm's 50-day simple moving average is $435.64 and its 200 day simple moving average is $460.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, equities analysts anticipate that Vertex Pharmaceuticals will post 15.58 EPS for the current fiscal year.
Insider Activity
In other news, EVP Ourania Tatsis sold 244 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the sale, the executive vice president now owns 67,695 shares of the company's stock, valued at approximately $30,805,286.70. This represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.20% of the company's stock.
Institutional Investors Weigh In On Vertex Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the stock. Northwest Investment Counselors LLC acquired a new stake in Vertex Pharmaceuticals during the third quarter worth approximately $25,000. Dunhill Financial LLC grew its stake in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 24 shares during the period. Highline Wealth Partners LLC acquired a new stake in Vertex Pharmaceuticals during the third quarter worth approximately $27,000. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals during the third quarter worth approximately $33,000. Finally, Brown Lisle Cummings Inc. acquired a new stake in Vertex Pharmaceuticals during the fourth quarter worth approximately $30,000. Institutional investors and hedge funds own 90.96% of the company's stock.
About Vertex Pharmaceuticals
(
Get Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
